177 related articles for article (PubMed ID: 38224371)
21. Mycosis fungoides and Sézary syndrome.
Jonak C; Tittes J; Brunner PM; Guenova E
J Dtsch Dermatol Ges; 2021 Sep; 19(9):1307-1334. PubMed ID: 34541796
[TBL] [Abstract][Full Text] [Related]
22. Outcome of allogeneic hematopoietic stem cell transplantation for mycosis fungoides and Sézary syndrome.
Mori T; Shiratori S; Suzumiya J; Kurokawa M; Shindo M; Naoyuki U; Katsuto T; Miyamoto T; Morishige S; Hirokawa M; Fukuda T; Atsuta Y; Suzuki R
Hematol Oncol; 2020 Aug; 38(3):266-271. PubMed ID: 32011008
[TBL] [Abstract][Full Text] [Related]
23. Mycosis Fungoides and Sézary Syndrome: Updates and Review of Current Therapy.
Kamijo H; Miyagaki T
Curr Treat Options Oncol; 2021 Jan; 22(2):10. PubMed ID: 33415447
[TBL] [Abstract][Full Text] [Related]
24. Long-term remission after allogeneic hematopoietic stem cell transplantation for refractory cutaneous T-cell lymphoma.
Guitart J; Wickless SC; Oyama Y; Kuzel TM; Rosen ST; Traynor A; Burt R
Arch Dermatol; 2002 Oct; 138(10):1359-65. PubMed ID: 12374543
[TBL] [Abstract][Full Text] [Related]
25. Management of relapsed cutaneous T-Cell lymphoma following allogeneic hematopoietic stem cell transplantation: Review with representative patient case.
Weiner DM; Lewis DJ; Spaccarelli NG; Clark RA; Nasta SD; Loren AW; Rook AH; Kim EJ
Dermatol Ther; 2022 Jul; 35(7):e15538. PubMed ID: 35477952
[TBL] [Abstract][Full Text] [Related]
26. Primary cutaneous T-cell lymphomas other than mycosis fungoides and Sézary syndrome. Part II: Prognosis and management.
Oh Y; Stoll JR; Moskowitz A; Pulitzer M; Horwitz S; Myskowski P; Noor SJ
J Am Acad Dermatol; 2021 Nov; 85(5):1093-1106. PubMed ID: 33945836
[TBL] [Abstract][Full Text] [Related]
27. Investigative drugs for the treatment of cutaneous T-cell lymphomas (CTCL): an update.
Ramelyte E; Dummer R; Guenova E
Expert Opin Investig Drugs; 2019 Sep; 28(9):799-809. PubMed ID: 31398295
[No Abstract] [Full Text] [Related]
28. Transformation of Mycosis Fungoides/Sezary Syndrome: Clinical Characteristics and Prognosis.
Vural S; Akay BN; Botsalı A; Atilla E; Parlak N; Okçu Heper A; Şanlı H
Turk J Haematol; 2018 Mar; 35(1):35-41. PubMed ID: 28533196
[TBL] [Abstract][Full Text] [Related]
29. Leukaemic variants of cutaneous T-cell lymphoma: Erythrodermic mycosis fungoides and Sézary syndrome.
Martinez XU; Di Raimondo C; Abdulla FR; Zain J; Rosen ST; Querfeld C
Best Pract Res Clin Haematol; 2019 Sep; 32(3):239-252. PubMed ID: 31585624
[TBL] [Abstract][Full Text] [Related]
30. Allogeneic stem-cell transplantation in patients with cutaneous lymphoma: updated results from a single institution.
Hosing C; Bassett R; Dabaja B; Talpur R; Alousi A; Ciurea S; Popat U; Qazilbash M; Shpall EJ; Oki Y; Nieto Y; Pinnix C; Fanale M; Maadani F; Donato M; Champlin R; Duvic M
Ann Oncol; 2015 Dec; 26(12):2490-5. PubMed ID: 26416896
[TBL] [Abstract][Full Text] [Related]
31. Roles of OX40 and OX40 Ligand in Mycosis Fungoides and Sézary Syndrome.
Kawana Y; Suga H; Kamijo H; Miyagaki T; Sugaya M; Sato S
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830466
[TBL] [Abstract][Full Text] [Related]
32. How we treat advanced stage cutaneous T-cell lymphoma - mycosis fungoides and Sézary syndrome.
Sethi TK; Montanari F; Foss F; Reddy N
Br J Haematol; 2021 Nov; 195(3):352-364. PubMed ID: 33987825
[TBL] [Abstract][Full Text] [Related]
33. Cutaneous T-cell lymphomas: 2023 update on diagnosis, risk-stratification, and management.
Hristov AC; Tejasvi T; Wilcox RA
Am J Hematol; 2023 Jan; 98(1):193-209. PubMed ID: 36226409
[TBL] [Abstract][Full Text] [Related]
34. Cutaneous T cell lymphoma-mycosis fungoides and Sezary syndrome: an update.
Parker SR; Bethaney JV
G Ital Dermatol Venereol; 2009 Aug; 144(4):467-85. PubMed ID: 19755952
[TBL] [Abstract][Full Text] [Related]
35. Mycosis fungoides and Sézary syndrome: 2019 update on diagnosis, risk-stratification, and management.
Hristov AC; Tejasvi T; Wilcox RA
Am J Hematol; 2019 Sep; 94(9):1027-1041. PubMed ID: 31313347
[TBL] [Abstract][Full Text] [Related]
36. A meta-analysis of patients receiving allogeneic or autologous hematopoietic stem cell transplant in mycosis fungoides and Sézary syndrome.
Wu PA; Kim YH; Lavori PW; Hoppe RT; Stockerl-Goldstein KE
Biol Blood Marrow Transplant; 2009 Aug; 15(8):982-90. PubMed ID: 19589488
[TBL] [Abstract][Full Text] [Related]
37. The Microenvironment's Role in Mycosis Fungoides and Sézary Syndrome: From Progression to Therapeutic Implications.
Pileri A; Guglielmo A; Grandi V; Violetti SA; Fanoni D; Fava P; Agostinelli C; Berti E; Quaglino P; Pimpinelli N
Cells; 2021 Oct; 10(10):. PubMed ID: 34685762
[TBL] [Abstract][Full Text] [Related]
38. Pathogenesis and Therapy of Primary Cutaneous T-Cell Lymphoma: Collegium Internationale Allergologicum (CIA) Update 2020.
Bobrowicz M; Fassnacht C; Ignatova D; Chang YT; Dimitriou F; Guenova E
Int Arch Allergy Immunol; 2020; 181(10):733-745. PubMed ID: 32690848
[TBL] [Abstract][Full Text] [Related]
39. Mogamulizumab in the treatment of advanced mycosis fungoides and Sézary syndrome: safety and efficacy.
Lewis DJ; Rook AH
Expert Rev Anticancer Ther; 2020 Jun; 20(6):447-452. PubMed ID: 32320304
[TBL] [Abstract][Full Text] [Related]
40. Induction of complete remission of advanced stage mycosis fungoides by allogeneic hematopoietic stem cell transplantation.
Masood N; Russell KJ; Olerud JE; Sabath DE; Sale GE; Doney KC; Flowers ME; Fefer A; Thompson JA
J Am Acad Dermatol; 2002 Jul; 47(1):140-5. PubMed ID: 12077596
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]